Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Weight change and long-term cardiovascular outcomes in overweight and obese patients after acute coronary syndromes.

European heart journal open·2026

Same author

Impact of care reorganisation during COVID-19 waves on non-COVID-19 inpatients in a Swiss hospital: a retrospective cohort study.

Swiss medical weekly·2026

Same author

Cranial and Systemic Manifestations of Giant Cell Arteritis: Two Sides of the Same Coin.

Cureus·2026

Same author

Environmental pollution, apolipoprotein A-1 autoantibodies and cardiovascular risk: evidence from a geospatial cross-sectional study.

Atherosclerosis plus·2026

Same author

Sex-related disparities in sepsis in western Europe: A systematic review and meta-analysis.

European journal of internal medicine·2026

Same author

Multi-biomarker approach for predicting cardiac magnetic resonance parameters at 30 days after ST-segment elevation myocardial infarction.

International journal of cardiology. Heart & vasculature·2026

Search research articles

Related Experiment Videos

[Beta-blocker therapy during acutely decompensated heart failure].

Damien Keller¹, David Carballo, Nicolas Garin

¹Service de médecine interne générale, Département de médecine interne, HUG, 1211 Genève 14.

Revue Medicale Suisse

|November 12, 2011

Summary

Beta-blocker therapy offers significant benefits for chronic heart failure patients, improving survival and reducing hospitalizations. Early initiation in acute heart failure is recommended, with continuation generally safe and beneficial.

Related Experiment Videos

Area of Science:

Cardiology
Pharmacology

Context:

Established benefits of beta-blocker therapy in chronic heart failure (CHF) include improved survival, quality of life, and reduced morbidity and hospitalizations.
Evidence supports early initiation of beta-blocker therapy during the same hospitalization for acute heart failure (AHF).

Purpose:

To summarize the established benefits and recommended use of beta-blocker therapy in both chronic and acute heart failure settings.
To discuss the implications of continuing beta-blocker therapy during acute heart failure episodes.

Summary:

Beta-blocker therapy is well-established for chronic heart failure, improving key clinical outcomes.
In acute heart failure, early initiation is supported, and maintaining therapy is generally not detrimental, potentially improving adherence.
Temporary discontinuation is reserved for specific severe conditions like cardiogenic shock or clinical deterioration.

Impact:

Maintaining beta-blocker therapy during acute heart failure episodes appears safe and may enhance long-term treatment adherence.
Further large-scale prospective trials are needed to confirm the mortality benefits of sustained beta-blocker use in acute heart failure.
This evidence supports current clinical guidelines for beta-blocker management in heart failure patients.